TOXICOLOGICAL INVESTIGATION, IDENTIFICATION, AND BIOACTIVITY
EVALUATION OF STEROIDAL ALKALOIDS DERIVED FROM VERATRUM
PARVIFLORUM
by
Jared Taylor Seale

A thesis
submitted in partial fulfillment
of the requirements for the degree of
Master of Science in Chemistry
Boise State University

August 2022

© 2022
Jared Taylor Seale
ALL RIGHTS RESERVED

BOISE STATE UNIVERSITY GRADUATE COLLEGE
DEFENSE COMMITTEE AND FINAL READING APPROVALS
of the thesis submitted by
Jared Taylor Seale
Thesis Title: Toxicological Investigation, Identification, and Bioactivity Evaluation of
Steroidal Alkaloids Derived from Veratrum parviflorum
Date of Final Oral Examination:

11 May 2022

The following individuals read and discussed the thesis submitted by student Jared Taylor
Seale, and they evaluated the student’s presentation and response to questions during the
final oral examination. They found that the student passed the final oral examination.
Owen McDougal, Ph.D.

Chair, Supervisory Committee

Lisa Warner, Ph.D.

Member, Supervisory Committee

Julia Oxford, Ph.D.

Member, Supervisory Committee

The final reading approval of the thesis was granted by Owen McDougal, Ph.D., Chair of
the Supervisory Committee. The thesis was approved by the Graduate College.

ACKNOWLEDGMENTS
The work presented in this thesis was made possible by those who came before
me and laid the foundations for this research, provided my training, and worked
alongside me. I would like to acknowledge Dr. Matthew Turner for his work regarding
the investigation of Veratrum californicum steroidal alkaloids. Many of the methods used
in this research were adapted from his publications. Thank you to the physicians at
Emory University for bringing this project to Dr. Owen McDougal’s lab, providing
patient and plant samples, and collaborating on a publication for this work. Dr. Shin Pu
was an indispensable resource regarding the collection of HPLC-MS data and cell
culture. Lastly, I wish to acknowledge the valuable insights and resources provided by
the members of my Supervisory Committee, Drs. Owen McDougal, Julia Oxford, and
Lisa Warner.

iv

ABSTRACT
Plants of the Veratrum genus have been used throughout history for their emetic
properties, rheumatism, and for the treatment of high blood pressure. However,
inadvertent consumption of these plants, which resemble wild ramps, induces life
threatening side effects attributable to an abundance of steroidal alkaloids. Several of the
steroidal alkaloids from Veratrum spp. have been investigated for their ability to
antagonize the Hedgehog (Hh) signaling pathway, a key pathway for embryonic
development and cell proliferation. Uncontrolled activation of this pathway is linked to
the development of various cancers, most notably basal cell carcinoma and acute myeloid
leukemia. Additional investigation of Veratrum spp. may lead to the identification of
novel alkaloids with potential to serve as chemotherapeutics. This project aimed to
identify steroidal alkaloids in V. parviflorum, perform a toxicological investigation for
the presence of these alkaloids in the blood and breast milk of patients who ingested V.
parviflorum, and evaluate the bioactivity of these alkaloids for inhibiting the Hh signaling
pathway. Four steroidal alkaloids were identified in the ethanolic extract of V.
parviflorum: cyclopamine, veratramine, jervine, and muldamine. Cyclopamine,
veratramine, and jervine were identified in patient blood while cyclopamine and
veratramine were identified in patient breast milk. A bioactivity assessment of the V.
parviflorum extract using Shh-Light cells suggested that there are additional compounds
within the plant that are antagonistic to the Hh signaling pathway.
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CHAPTER ONE: VERATRUM PARVIFLORUM: AN UNDEREXPLORED SOURCE
FOR BIOACTIVE STEROIDAL ALKALOIDS
1. Introduction
Most modern therapeutics have originated from a treasure trove of secondary
metabolites extracted from natural products of terrestrial or marine origin. An estimated
70,000 plant species have been used throughout history for medicinal purposes and more
than 3,000 plants are reported to contain compounds with anticancer properties.1,2 The
Veratrum californicum derived steroidal alkaloid, cyclopamine, was first isolated in 1965
and later identified as an inhibitor of the protein Smoothened (Smo), which is a critical
protein in the Hedgehog signaling pathway.3,4 Since this discovery, a new class of Food
and Drug Administration (FDA) approved chemotherapeutics called Hedgehog pathway
inhibitors have been developed for the treatment of cancers, most prominently basal cell
carcinoma and acute myeloid leukemia.5 Plants from the genus Veratrum, including V.
viride, V. album, V. nigrum, and V. californicum have been extensively studied, and
found to be rich sources for unique steroidal alkaloids (>100 alkaloids/plant), with
approximately 20% of these secondary metabolites being characterized.6 Here we present
a consolidated review of the morphological, ecological, and phytochemical information
regarding the sparsely studied Veratrum spp., V. parviflorum.
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1.1 Background
1.1.1 Veratrum Genus
The Veratrum genus is comprised of perennial flowering herbs located
predominantly in the Northern hemisphere.7 These plants are found throughout temperate
regions of North America and northern temperate to arctic regions in Eurasia.7
Depending on taxonomic treatment, the number of species varies between 17-45 species,
which can be divided into four species complexes: V. album L., V. nigrum L., V. mackii
Regal, and V. viride Aiton.7,8 Wide variability in taxonomic treatment may be attributed
to dissimilarity in morphology, including leaves, tepals, and perigonal nectaries, and
habitats, including rocky tundra, bogs, meadows, riverbanks, swamps, and deciduous
forest slopes.7 Veratrum may be further divided into two major sections: Veratrum sect.
Veratrum [Clade B] and Veratrum sect. Fuscoveratrum [Clade C] (Figure 1.1).
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Figure 1.1

Veratrum spp. separated by classification in Veratrum sect.
Fuscoveratrum and Veratrum sect. Veratrum.

1.1.2 Medicinal Relevance
Traditional medicines have utilized Veratum spp. plants as a source of
therapeutically active compounds for centuries.6,9 Chinese medicine utilized V. nigrum in
a medicinal concoction, referred to as Li-lu, to treat conditions including aphasia
resulting from apoplexy, wind-type dysentery, jaundice, scabies, and chronic malaria.10
The roots and rhizome of V. album subsp. lobelianum are described in the first
Pharmacopoeia Rossica as a traditional Russian medicine that is made into a tincture or
ointment for the treatment of head lice, scabies, neuralgic and rheumatic pain, eczema, or
fevers.11 This plant has also been used as an antiparasitic in cattle against
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hypodermatosis.11 V. album has seen widespread use in Eurasia.12 The Greeks used a
powdered form of V. album to induce sneezing and for psychological diseases such as
depression and epilepsy.12,13 An alcohol extract of V. album’s roots was used in Italy as
an antirheumatic.12 In Iranian folk tradition, a paste of V. album roots was used to relive
headaches and neuralgic pains.12 In North America, Native American tribes including the
Shoshone, Bella Coola, Cherokee, Gitksan, Haisla, Hanaksiala, Iroquois, Kitasoo,
Okanagan-Colville, Oweekeno, Quinault, Salish Thompson, and Tsimishian used the
crushed roots of V. viride as an antirheumatic, to treat snake bite wounds, to make a tea
for venereal diseases, and as an analgesic for sore throats and colds.6,12 Table 1.1 presents
a comparison of several Veratrum spp. including identified steroidal alkaloids and
traditional medical applications.
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Table 1.1

A Comparison of Identified Steroidal Alkaloids and Traditional
Medicinal Applications for Several Veratrum spp.
Alkaloids Identified

Traditional
Medical
Applications

References

V. nigruma

Epiverazine, veratramine,
verazine

Apoplexy,
wind-type
dysentery,
jaundice,
scabies, chronic
malaria

10,14

V. albumb

Verazine, jervine,
pseudojervine, rubijervine,
veralosine, veralosidine,
verabenzoamine,
veratroilzigadenine, 15-O-(2methylbutyroyl)germine,
veralosinine, veratramine,
veratridine, cevadine

Head lice,
scabies,
neuralgic pain,
eczema, fever,
hypodermatosis,
rheumatism,
headache

11,12,13,14

V. virideb

Veratramine,
isorubijervosine,
pseudojervine, rubijervine

Rheumatism,
venereal
diseases,
analgesic

6,12,14

V.
californicumb

Cyclopamine, veratramine,
muldamine, isorubijervine,
cycloposine, veratrosine

None reported

6,14

V. parvilforuma

Cyclopamine, veratramine,
veratridine, verazine

None reported

15

Veratrum spp.

a
b

Species within Veratrum sect. Fuscoveratrum [Clade C].
Species within Veratrum sect. Veratrum [Clade B].
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2. Veratrum parviflorum
2.1 Taxonomy and Physical Characteristics
Veratrum (Melanthium) parviflorum, commonly known as mountain
bunchflower, has a complex history regarding its classification in the Veratrum and
Melanthium genera due to variation in morphological constraints set by botanists.7,16 To
provide a more defined taxonomy of Veratrum spp., the nuclear ribosomal internal
transcribed spacers (ITS) were analyzed and correlated to traditional taxonomic
classifications including flower color and geographical location.7 The strict and bootstrap
consensus trees were almost identical, except for V. parviflorum. The strict consensus
suggested that V. parviflorum formed a subclade and was sister to V. latifolium, V.
virginicum, and V. woodii, whereas the bootstrap consensus suggested that this species
falls outside of the clade, forming a polytomy with the V. maackii and V. micranthum
complexes.7
V. parviflorum is identified in nature using defined morphological traits. The stem
is slender and 2 to 5 feet tall.16,17 A pseudostem is formed by the overlapping sheaths of
the leaves which are broad (2-4 inches wide), petiolate, obscurely plicate, and have a blue
tint adaxially.7,16 The tepals are pale green to olive green, narrowly rhombic oblanceolate,
with entire margins, gradually attenuated at base, filaments adnate, gland bilobed, diffuse,
and dark (Figure 1.2).7
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Figure 1.2
V. parviflorum in situ before blooming (left). In the later stages of
growth, a stem protrudes from the base of the plant and blooms with pale green
flowers.20
2.2 Geographic Location and Herbivory
V. parviflorum is found in the Southeastern regions of North America.15-19 This
species grows in rich deciduous forests (800-2030 m) in the mid-Appalachians, including
parts of Alabama, Georgia, Kentucky, North Carolina, South Carolina, Tennessee,
Virginia, and West Virginia.15,16 The states of Alabama, Kentucky, and West Virginia
have classified the conservation status of V. parviflorum as critically imperiled (S1),
imperiled (S2), and vulnerable (S3), respectively.18,19 This plant is most easily discovered
in the spring when it reaches peak germination.21 Unfortunately, V. parviflorum growth
season coincides with wild ramps (Allium tricoccum), and has led to accidental ingestion
of V. parviflorum, resulting in cardiac and gastrointestinal toxicity.15 Despite inducing
toxic effects when ingested by humans, white-tailed deer have been observed to consume
the entire inflorescences of this species.16,22
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2.3 Toxicity
Cases of Veratrum poisoning are found extensively within literature, however, V.
parviflorum has only been implicated in one case of poisoning in the United States.15
Symptoms of Veratrum poisoning generally include nausea, vomiting, diarrhea,
hypotension, bradycardia, hypopnea, paresthesia, or death if medical attention is not
received.15,23-32 Treatment for Veratrum poisoning is generally symptomatic and
supportive, and may include the administration of atropine, intravenous fluids,
vasopressors, activated charcoal, and promethazine.15,24-30,32 Although digoxin immune
Fab has been used for treating symptoms of cardiotoxicity similar to those observed in
cases of Veratrum poisoning, it has been suggested that medical providers should not
unnecessarily administer DigiFabTM as they do not bind steroidal alkaloids extracted from
V. viride.32 Furthermore, MultigentTM digoxin immunoassay reagent antibodies
demonstrated cross-reactivity with the alkaloids, resulting in false-positive tests.32 Table
1.2 presents a summary of treatments for several cases of Veratrum poisoning.
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Table 1.2
Summary of Several Cases of Veratrum Poisoning Including
Causative Plant, Symptoms, and Treatment
Veratrum spp.
Ingested

V.
parviflorum

Symptoms

Treatment

References

Nausea, vomiting, hypotension,
bradycardia

Antiemetics,
intravenous fluid
resuscitation,
digoxin immune
Fab

15

intravenous fluid
resuscitation,
atropine,
promethazine,
dopamine infusion

23,24, 26,32

Activated
charcoal,
antiemetics,
intravenous fluid
resuscitation,
thiethylperazine,
atropine,
prednisolone,
hydrocortisone,
tocopherol,
unithiol, digoxin
immune Fab

25,27-31

Nausea, vomiting, diaphoresis,
lightheadedness, bilateral
V. viride

V. album

retrobulbar headache, leg
spasms, hypotension,
bradycardia, paresthesia,
dyspnea, sluggishly reactive 23 mm pupils

Nausea, vomiting, headache,
diarrhea, bradycardia,
dizziness, paresthesia, blurred
vision, abdominal pain,
clouded consciousness, pyrosis,
atrioventricular dissociation,
death
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The cardiotoxic effects from consuming Veratrum spp. are primarily due to the
steroidal alkaloids produced by the plant.33 These steroidal alkaloids are recognized for
their tendency to bind to the type 2 receptor site of voltage gated sodium ion channels in
vertebrate organisms.33,34 Once bound, the resting membrane potential is depolarized,
causing excitable membranes to fire repetitively.33-35 Symptoms including bradycardia
and hypotension are caused by the alkaloids interacting with cardiac receptors in the left
ventricle posterior wall and the baroreceptor area of the coronary sinus while
depolarization in the vagus nerve can induce bradycardia, hypotension, and dyspnea.33,36
Additional symptoms resulting from depolarization of the nerve cells may comprise of
paresthesia, numbness, and vomiting.33 The triad of symptoms including bradycardia,
hypotension, and dyspnea caused by Veratrum poisoning is referred to as a BezoldJarisch reflex.6,33,37,38
Veratrum steroidal alkaloids are recognized as antagonistic to the Hedgehog
signaling pathway.39-41 In the late 1950s, sheep herders in the South Central and
Southwestern alpine meadows of Idaho observed that 1-25% of their lambs were born
with cyclopean-type developmental defects.42 These malformations were originally
thought to be congenital, however, further investigations revealed that they resulted from
pregnant ewes feeding on V. californicum between the 10th and 15th days of
gestation.42,43 The Veratrum steroidal alkaloids cyclopamine, jervine, cycloposine, and
veratrosine were identified as the causative teratogenic agents.44 Veratrum steroidal
alkaloids exert teratogenic effects via antagonism of the Hedgehog signaling pathway by
directly binding to the transmembrane protein Smoothened (Smo).4,39 The binding of the
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small molecule to Smo takes place in the deep seven-transmembrane pocket of Smo,
inhibiting activation by membrane sterols.45
2.4 Phytochemistry
There is a lack of published information regarding the steroidal alkaloid content in
V. parviflorum. Currently, only four alkaloids have been identified in an extract of its
roots and rhizome.15 The four alkaloids including cyclopamine, veratramine, verazine,
and veratridine are not novel to the Veratrum genus and have been investigated for a
variety of bioactive properties.
2.4.1 Cyclopamine
Cyclopamine (Figure 1.2A) was isolated from V. grandiflorum in 1965 and was
the first molecule identified to inhibit the Hedgehog signaling pathway.3,4,6,46 Since its
discovery, cyclopamine has also been identified in V. californicum and V.
parviflorum.6,14,15,41,44 Cyclopamine is classified as a jervanine type steroidal alkaloid
with a C-nor-D-homosteroidal skeleton where the C and D rings of the steroidal
backbone are five and six membered rings, respectively.6 Jervanine type alkaloids feature
a tetrahydrofuran E-ring that links the nitrogen containing F-ring to the D-ring through a
spiro-carbon at the cyclic ether.6 This compound has been observed to inhibit Hedgehog
signaling in Shh Light II cells, inhibit the growth of breast cancer, induce apoptosis in
human prostate cancer, increase the expression of death receptor 5 in tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) resistant gastric cancer cells, induce
apoptosis and COX-2 overexpression via PKC activation in HEL and TF1a human
erythroleukemia cell lines, and induce growth inhibition in human carcinogenesis of
cholangiocarcinoma cell lines.41,47-51 Cyclopamine has shown promise as a human
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chemotherapy, however, it has limited use due to its low solubility in aqueous solutions,
and instability in acidic conditions.52 To addresses these limitations, semi-synthetic
approaches have been undertaken to increase potency and solubility.53,54 The
cyclopamine derivative KAAD-cyclopamine included the addition of a 3-keto,Naminoethyl aminocaproyl dihydrocinnamoyl (KAAD) functional group to the F-ring
nitrogen, resulting in a 10-20 fold increase in potency.52,53 A cyclopamine-tartrate salt
was developed to increase the solubility of the compound in water.52,54 The cyclopaminetartrate salt was more soluble in water at about 5 mg/mL, a higher LD50 of 62.5 mg/kg of
body weight compared to that of cyclopamine which is 43.5 mg/kg and had a lower
tumor area value in Krt6a-cre: Ptch1neo/neo mice.54 Cyclopamine has been used as a
molecular scaffold for the semi-synthetic derivative patidegib, that is currently
undergoing phase III clinical trials. Patidegib, formerly known as saridegib and IPI-926,
has received orphan drug approval for the treatment of nevoid basal cell carcinoma.5,55

Figure 1.3

Chemical structures of A) cyclopamine, B) veratramine, C) verazine,
and D) veratridine.
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2.4.2 Veratramine
Veratramine (Figure 1.3B) has been identified in V. parviflorum, V. viride, V.
oxysepalum, V. nigrum L., V. californicum, and V. grandiflorum.15,41,56-59 Similar to
cyclopamine, veratramine contains a C-nor-D-homosteroidal skeleton, however, it is
further categorized as a veratranine type alkaloid.6 In comparison to jervanine-type
alkaloids, those of the veratranine-type feature an aromatized D-ring and lack a
tetrahydrofuran E-ring that connects the piperidine ring to the D-ring. Veratramine is a
lipid-soluble alkaloid that exhibits a range of bioactivities.60 This alkaloid was observed
to cause DNA damage in the cerebellum and cerebral cortex of mice in a dose-dependent
trend through the generation of reactive oxygen species, inhibit Hedgehog signaling in
Shh light II cells, reduce the growth, proliferation, and migration of the PC-3 human
metastatic prostate cancer cell line, and induce autophagy-mediated apoptosis by
inhibiting PI3K/Akt/mTOR signaling in HepG2 cells.14,41,60-63 One study regarding the
metabolism of veratramine in male Sprague–Dawley rats suggested elimination of the
alkaloid primarily occurred through phenyl mono-oxidation, hydroxylation, and
methylation.60 The phenyl-oxidation metabolite of veratramine was proposed to lead to
the formation of reactive oxygen species that oxidize DNA and proteins.60
2.4.3 Verazine
Verazine (Figure 1.3C) is a precursor to steroidal alkaloids, including
cyclopamine and veratramine, found across the Melanthiaceae and Solanaceae plant
families.6,15,64-68 This compound is classified as a verazine type steroidal alkaloid in the
cyclopentanophenanthrene skeleton ring system.6 The cyclopentanophenanthrene
skeleton features a ring scaffold typical of cholesterol where the C-ring and D-ring are six
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and five membered, respectively.6 Verazine type alkaloids are differentiated from
additional cyclopentanophenanthrene skeleton alkaloids by the presence of an imine
containing ring.6 The importance of verazine to the biosynthesis of Veratrum steroidal
alkaloids has promoted efforts to elucidate its biosynthetic production from cholesterol.68
Augustin et al. identified cholesterol 22-hydroxylase (CYP90B27), 22hydroxycholesterol, 26-hydroxylase/oxidase (CYP94N1), 22-hydroxycholesterol-26-al
transaminase (GABAT1), and 22-hydroxy-26-aminocholesterol 22-oxidase (CYP90G1)
as the four enzymes that transform cholesterol into verazine.68 Although these efforts
have illustrated how verazine forms, proceeding steps in the biosynthetic formation of
additional steroidal alkaloids remain largely unexplored. Kaneko et al. performed a series
of studies that observed the conversion of products within the biosynthetic pathway,
however, the mechanisms in which these conversions take place remain unknown.69-76
Verazine has not been studied for potential anticancer properties, however, the alkaloid
does exhibit antifungal and melanogenesis inhibitory properties.66,67 The growth of
Candida albicans and Trichophyton rubrum was inhibited at minimum inhibitory
concentrations of 6.2 µg/mL and 3.1 µg/mL, respectively.67 Furthermore, melanogenesis
in B16 F1 mouse melanoma cells were inhibited with an IC50 of <1 µg/mL.66 Verazine
also showed inhibitory activity for Sc7 yeast, however, it proved to be cytotoxic in an M109 cell line with an IC50 of 12.5 µg/mL.64
2.4.4 Veratridine
Veratridine (Figure 1.3D) has been identified in V. album, V. viride, V.
parviflorum, and Schoenocaulon officinale.15,31,77,78 This compound is classified as a
cevanine type alkaloid with a C-nor-D-homosteroidal skeleton.6 The cevanine alkaloids
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are defined by the presence of a six membered E-ring, are highly hydroxylated, and a
hemiketal linkage between C4 and C9.6 This compound is primarily recognized as one of
the major alkaloids contributing to the cardiotoxic effects from Veratrum
poisoning.15,27,31,79 Veratridine has been identified as an agonist of voltage-gated sodium
ion channels.80 The compound binds to the type 2 receptor of voltage-gated sodium ion
channels, leading to membrane depolarization and repetitive firing of the nerve.33-35,80
Unlike cyclopamine and veratramine, veratridine has not been observed to inhibit
Hedgehog signaling through antagonism of Smo. Belgacem and Borodinsky used
veratridine to study the effects of a Ca2+ spike on Gli transcriptional activity.81
Veratridine selectively inhibits voltage-gated Na+ ion channels resulting in an increase of
Ca2+ spike activity and diminished Gli levels, which downregulates Sonic hedgehog
(Shh) signaling.81 In contrast, if voltage-gated Na+ and Ca2+ ion channels were blocked,
Gli transcriptional activity was increased, resulting in the upregulation of Shh signaling.81
These results suggested that Shh signaling may be selectively regulated by a Veratrum
steroidal alkaloid in mechanisms other than Smo antagonism.
3. Conclusion
Veratrum spp. have been investigated for their potential to inhibit the growth of
cancers, such as basal cell carcinoma and acute myeloid leukemia, resulting from
aberrant activation of the Hedgehog signaling pathway. Although species including V.
viride, V. album, V. nigrum, and V. californicum have been studied extensively, there is
limited information regarding the phytochemistry of V. parviflorum. Only four alkaloids
(cyclopamine, veratramine, verazine, and veratridine) with known bioactivities have been
identified in V. parviflorum, however, over forty-three prominent peaks were observed in
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the chromatogram of its extract.15 A combined effort to characterize these unknown
alkaloids and assess their capability to antagonize Hh signaling may yield a compound
suitable for further study.
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CHAPTER TWO: VERATRUM PARVIFLORUM POISONING: IDENTIFICATION
OF STEROIDAL ALKALOIDS IN PATIENT BLOOD AND BREAST MILK
1. Abstract
1.1 Introduction
The Veratrum genus is composed of plants containing a diverse set of steroidal
alkaloids. Ingestion of Veratrum plant material has been utilized for centuries as herbal
medicines, however the alkaloids have such a low therapeutic index that their use in
modern medicine has remained exploratory. Here we report an incident of inadvertent
ingestion of V. parviflorum by hikers on the Appalachian trail in Georgia that allowed
detection, and in several instances identification of alkaloids from the plant, and correlate
their presence within patient blood and breast milk specimens.
1.2 Case History
Eight patients, four male and four female, were reported to the Georgia Poison
Center in the spring of 2020 and 2021 with symptoms requiring emergent medical
attention after ingestion of Veratrum parviflorum. All patients believed the plants to be a
local native species of wild leek, Allium tricoccum, locally known as ramps. Plants were
identified using photographs as well as fresh and cooked plant material provided by
patients, in consultation with botanists at the University of Georgia Herbarium. Written
consent was obtained from all patients for collection of blood and breast milk specimens
for laboratory identification of Veratrum alkaloids.
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1.3 Methods
V. parviflorum plant material, and patient blood and breast milk were analyzed by
high performance liquid chromatography-quadrupole time-of-flight mass spectrometry
(HPLC-QTOF) to identify steroidal alkaloids.
1.4 Results
The V. parviflorum extract was confirmed to contain cyclopamine, veratramine,
jervine, and muldamine. Of these alkaloids identified in the plant, cyclopamine, jervine,
and veratramine were detected within patient blood, and cyclopamine and veratramine
were observed to be present in breast milk.
1.5 Discussion
Toxicity resulting from Veratrum steroidal alkaloids has primarily been reported
from V. album and V. viride. This is the second report of V. parviflorum poisoning. The
present work reports for the first time the presence of muldamine and jervine within V.
parviflorum. This work provides the first instance of identification of Veratrum alkaloids
in breast milk.
1.6 Conclusion
V. parviflorum toxicity was observed to cause nausea, vomiting, hypotension,
bradycardia, abdominal pain, light-headedness, blurred vision, and tingling in the arms.
Treatment included the administration of digoxin immune Fab, intravenous (IV) fluids,
antiemetics, atropine, norepinephrine, ondansetron, and dopamine.
2. Introduction
The Veratrum genus is comprised of 14-45 distinct species of woodland and
alpine perennial herbs located throughout temperate regions of the northern
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hemisphere.6,7,14 Nine species, or species complexes, of Veratrum may be found in North
American meadows, swamps, alpine forests, and riverbanks, including V. album, V.
californicum, V. viride, V. parviflorum, and V. tenuipetalum.6,7,14,82 These plants have
been incorporated into traditional medicines for centuries due to powerful physiological
effects resulting from their diverse mixture of steroidal alkaloids. Over 200 unique
steroidal alkaloids have been identified in Veratrum spp. and can be separated into two
distinct structural skeletons: C-nor-D-homosteroidal skeleton and
cyclopentanophenanthrene skeleton (Figure 2.1).6,82

Figure 2.1

Representative steroidal alkaloids from Veratrum spp. categorized by
structure template.

Veratrum steroidal alkaloids are primarily recognized for their propensity to bind
voltage gated sodium channels in vertebrate organisms.33 German physiologists Albert
von Bezold and Ludwig Hirt first observed the hypotensive and bradycardic effects of
veratrine administration on the heart of a rabbit in 1867, however it took until 1939
before Jarisch and Richter confirmed the mechanism by which Veratrum steroidal
alkaloids act on heart muscle.6,36,38 In their definitive work, Jarish and Richter identified
that the effects of veratrine, a mixture of Veratrum derived alkaloids, resulted from reflex
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action in the ventricles of the heart and transmission by the afferent and efferent
pathways of the vagus nerve.36 The symptoms of bradycardia, vasodilation, and
hypotension resulting from cardiac receptor stimulation is now termed the Bezold-Jarisch
reflex.6,33,37
Indigenous communities of North America are reported to have developed
medicines utilizing Veratrum plant material. Most notably, V. viride has been used to
treat a variety of conditions including boils, ulcers, pain, rheumatism, and venereal
diseases.6,83 Interestingly, a non-medicinal application of Veratrum plants was observed
by Charles Osgood in 1835. As part of the election of Native American leaders, the
rhizome of V. viride was made into a concoction that was ingested by candidates and
those who resisted the extract’s emetic effects the longest were considered most fit to
lead.84
Despite recognition as an ingredient in potent traditional medicines, the history of
Veratrum spp. is rife with accidental poisoning. Veratrum intoxication is most often due
to inadvertent consumption as a result of misidentification during foraging.15,23-30 Cases
of V. viride poisoning are reported to have occurred due to mistaking the plant for
Symplocarpus foetidus (skunk cabbage), Phytolacca americana (pokeweed), Allium
ampeloprasum (wild onion), and Allium tricoccum (ramps).23,24,26 Likewise, V. album, a
species most prominently found in northern Eurasia and localized regions of Alaska, is
reported to have been misidentified as Allium ursinum (wild onion) and Gentiana lutea
(yellow gentian).27,30 Most cases of poisoning manifest with symptoms including
diarrhea, nausea, vomiting, and a Bezold-Jarisch reflex (bradycardia, hypopnea, and
hypotension). Patients with mild symptoms typically respond well to symptomatic and
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supportive treatments with intravenous fluids and antiemetics, but those with
symptomatic bradycardia or hypotension may require treatment with atropine or
vasopressors.15,23-30
V. parviflorum (Appalachian Bunchflower) may be found in the moist, deciduous
forested slopes (800-2000 m) of the southern Appalachian Mountains. Characteristics of
this plant include shortened rhizome (0.3-6 cm), narrow stem with lengths of 0.5-1.5 m,
broadly oblanceolate to obovate leaves, and green-yellow to dark green flowers (Figure
2.2).8,15,17

Figure 2.2

In situ Veratrum parviflorum (left) and plant material collected in
April 2020 for steroidal alkaloid analysis (right).20

In April 2015, two patients presented to a Georgia hospital with Veratrum
poisoning resulting from erroneous identification of V. parviflorum as Allium
tricoccum.15 In addition to a Bezold-Jarisch reflex, neurological symptoms including taste
disturbance, vertigo, dysarthria, and vision changes were observed. These neurological
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symptoms have not been reported for previous cases of toxicity with V. viride or V.
album.23-27,29,30 Analysis of V. parviflorum biomass identified verazine, veratramine,
veratridine, and cyclopamine, all of which have been previously observed in Veratrum
species. Due to the appearance of atypical neurological symptoms and a lack of
information regarding the phytochemical profile of V. parviflorum, it was hypothesized
that additional steroidal alkaloids, beyond those previously detected from patients, may
be observed. The present study investigated eight cases of V. parviflorum poisoning
resulting from the misidentification of plant material. Patient serum and breast milk was
collected over the course of inpatient treatment and analyzed using high performance
liquid chromatography-quadrupole time of flight mass spectrometry (HPLC-QTOF).
3. Case History
Eight patients were reported to the regional poison center in the spring of 2020
and 2021 with symptoms requiring emergent medical attention after ingestion of
Veratrum parviflorum. All patients believed the plants to be a local native species of wild
leek, Allium tricoccum, locally known as ramps. Plants were identified using
photographs as well as fresh and cooked plant material provided by patients, in
consultation with botanists at the University of Georgia Herbarium. Written consent was
obtained from all patients for collection of blood and breast milk specimens for
laboratory identification of Veratrum alkaloids. Clinical findings are summarized in
Table 2.1.
A 34-year-old man (patient 1) and 34-year-old woman (patient 2) presented to a
community emergency department (ED) in April 2020 after ingesting plants thought to be
ramps (Allium tricoccum) that they foraged in Union County, Georgia and sauteed in oil.
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Patient 1 developed abdominal cramping with nausea and profuse vomiting
approximately one hour after ingesting a half cup of cooked plants. He also reported
visual disturbances, including a yellow tint to his vision and halos. His blood pressure on
arrival was 78/40, and heart rate was 43 beats per minute, occasionally dropping to the
30s. A 12-lead EKG showed sinus bradycardia with a rate of 54.
Patient 2 developed nausea and vomiting approximately two hours after ingestion
of approximately one tablespoon of cooked plants. Her initial blood pressure was 90/52,
and heart rate was 60 beats per minute. Her 12-lead EKG showed sinus bradycardia with
heart rate of 56, with incomplete right bundle branch block.
Both patients were treated with IV fluid resuscitation and antiemetics. Their
clinical presentation was concerning for cardiac glycoside ingestion, and the plant leaf
material was initially noted to resemble lily of the valley (Convallaria majalis). Both
patients were treated empirically with five vials of digoxin immune Fab (DIF) (200 mg)
IV. Serum digoxin levels were undetectable in both patients.
Patient 1 did not improve after receiving DIF. He was unable to receive more DIF
as the hospital pharmacy had no more in stock. He received atropine 0.4 mg IV and a
norepinephrine infusion for persistent symptomatic bradycardia and hypotension. His
hemodynamics improved with vasopressor support, and his nausea and vomiting
resolved. He was transferred to an intensive care unit (ICU) at a tertiary care hospital,
where he was observed overnight. He remained hemodynamically stable and
norepinephrine was weaned off. All symptoms resolved approximately 12 hours after
arrival, and he was discharged home.
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Patient 2 responded well to ondansetron, IV fluids, and DIF with full resolution of
her symptoms. She was observed in the ED for approximately five hours and remained
hemodynamically stable. She was discharged home. As she was breastfeeding at the time,
she agreed to provide breast milk samples from the time of exposure for further analysis,
in addition to blood samples collected at the hospital.
Patients 3-6 were a family of four who presented in April 2020, consisting of a
50-year-old man (patient 3), 53-year-old woman (patient 4), 15-year-old daughter (patient
5), and 18-year-old son (patient 6). They foraged and ate plants thought to be ramps
found along the Benton MacKaye Trail on Flat Top Mountain in Epworth, Fannin
County, Georgia. Approximately six to seven whole plants including the leaves, stem,
and root material were sauteed with olive oil and consumed. All family members
developed symptoms within 3.5 hours of ingestion and presented to an ED approximately
14 hours after ingestion.
Patient 3 developed nausea with multiple bouts of profuse vomiting with
epigastric pain 3.5 hours after ingestion of two plants. He also developed generalized
weakness and lightheadedness that was worse with exertion. Initial vitals showed blood
pressure of 117/88 and heart rate 52. EKG showed sinus bradycardia with rate of 44 and
first degree block. Labs were significant for elevated serum creatinine of 1.92 mg/dL
(reference range 0.7 – 1.3), total bilirubin of 1.3 mg/dL (reference range 0.3-1), and
undetectable digoxin level. He was treated symptomatically with ondansetron and fluids.
He remained stable and symptoms resolved. Serum creatinine improved to 1.52 mg/dL
the following day, although total bilirubin increased to 1.6 mg/dL. He was discharged
home approximately 36 hours after ingestion.
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Patient 4 ate one leaf and developed nausea with mild epigastric discomfort
approximately one to two hours after ingestion. Her symptoms persisted for
approximately 16 hours before resolving spontaneously. On arrival at the ED, blood
pressure was 134/75, heart rate 105. EKG showed normal sinus rhythm with a rate of 75.
Lab studies showed no acute abnormalities, with undetectable digoxin level.
Patient 5 reported eating one plant that included three leaves, stalk, and roots. She
developed nausea and diffuse abdominal pain 2.5 hours after ingestion, but had no
vomiting or other symptoms. Initial blood pressure in the ED was 139/66, with heart rate
of 84. EKG showed sinus bradycardia with a ventricular rate of 53. Blood lab analyses
revealed a positive digoxin assay with a reported level of 0.4 ng/mL (reference <2
ng/mL).
Patient 6 developed nausea two hours after ingesting six leaves, followed by three
episodes of profuse vomiting. He also reported palpitations with lightheadedness,
diaphoresis, and blurred vision as well as one bout of loose stool. Initial blood pressure in
the ED was 104/51, and heart rate was 58. EKG showed normal sinus rhythm, rate 63.
Lab studies showed slightly elevated total bilirubin of 1.7 mg/dL, but otherwise normal
with negative digoxin assay. He received ondansetron and IV fluid hydration, with
subsequent resolution of nausea and lightheadedness.
Patient 7 is a 57-year-old female who picked V. parviflorum plants mistaken for
ramps in Hiwassee, Cherokee County, North Carolina. She ate above-ground leafy
material from two plants that were blanched in water and seasoned with a dressing. She
developed nausea, vomiting, diarrhea, and cramping epigastric pain within four hours of
ingestion. She received oral promethazine and ondansetron from her primary care
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physician, but symptoms persisted. She presented to the ED eight hours after ingestion
and was hypotensive, with blood pressure of 84/49, heart rate 91. Labs showed mild
hypokalemia with potassium of 3.3 mEq/L, and undetectable digoxin. She continued to
have intractable vomiting with persistent hypotension, with lowest blood pressure of
78/41, but no bradycardia. She was admitted and treated with IV fluids and
metoclopramide, but did not require vasopressors. EKG showed normal sinus rhythm
with rate of 96 and normal intervals. Her symptoms resolved with supportive care and
she was discharged 42 hours after ED presentation.
Patient 8 is a 58-year-old female who also consumed false hellebore leaves boiled
in water. She developed vomiting, lightheadedness, chest discomfort, generalized
weakness, and a sensation of pressure with tingling in the right arm 1.5 hours after the
meal. She initially presented to an urgent care clinic where she was noted to be
hypotensive, and transferred to an ED. Blood pressure on arrival was 80/50, with a heart
rate of 46. She received atropine 0.5 mg IV with transient improvement of her heart rate
to 80, and blood pressure of 130/70. Her heart rate decreased to the 40s again in the ED
and blood pressure was 80/50. She received another dose of atropine 0.5 mg IV and a 1 L
IV fluid bolus. Labs showed no acute abnormalities, with undetectable digoxin. EKG
revealed sinus bradycardia. She was started on a dopamine infusion at 15 mcg/min and
admitted to the ICU. She remained hemodynamically stable with heart rate in the 60s and
70s with normal blood pressure overnight. The dopamine drip was weaned off over 24
hours, with full resolution of all symptoms.

Age/Gender

34M

34F

50M

1

2

3

Time to
Symptom
Onset

1 hour

2 hours

3.5 hours

Clinical Effects

Nausea, vomiting,
abdominal cramping,
hypotension,
bradycardia

Nausea, vomiting,
hypotension,
bradycardia

Nausea, vomiting,
epigastric pain,
generalized
weakness,
lightheadedness,
bradycardia

Summary of Patients and Clinical Presentation

Patient

Table 2.1

Creatinine 1.92
mg/dL (ref 0.71.3), total
bilirubin 1.6
ng/dL (ref 0.3-1)

No acute
abnormalities

No acute
abnormalities

Lab Findings*

Sinus
bradycardia,
rate 44, 1st
degree AV
block

Sinus
bradycardia,
rate 56,
incomplete
right bundle
branch block

Sinus
bradycardia,
rate 54

EKG

IV fluids,
ondansetron

Digoxin immune
Fab, IV fluids,
ondansetron

Digoxin immune
Fab, IV fluids,
promethazine,
atropine,
norepinephrine

Treatment
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15F

18M

57F

58F

5

6

7

8

1-2 hours

2.5 hours

2 hours

4 hours

1.5 hours

Nausea, diffuse
abdominal pain,
bradycardia
Nausea, vomiting,
palpitations, lightheadedness,
diaphoresis,
blurred vision,
loose stool
Nausea, vomiting,
diarrhea,
epigastric pain,
hypotension
Nausea, vomiting,
light-headedness,
chest discomfort,
generalized
weakness, arm
tingling,
hypotension,
bradycardia

No acute
abnormalities

Potassium 3.3
mEq/L (ref
3.5-5)

Total bilirubin
1.7 ng/dL (ref
0.3-1)

Digoxin level
0.4 ng/mL (ref
<2)

No acute
abnormalities

Sinus
bradycardia

Normal
sinus
rhythm, rate
96

Normal
sinus
rhythm, rate
63

Sinus
bradycardia,
rate 53

Normal
sinus
rhythm, rate
75

Atropine, IV
fluids,
dopamine

IV fluids,
metoclopramide

IV fluids,
ondansetron

None

None

* All patients had lab tests including serum electrolytes, BUN/creatinine, liver enzymes, complete blood count, and digoxin level. Normal results are not listed in
this table.

53F

4

Nausea, mild
epigastric
discomfort
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4. Materials and Methods
4.1 Root and Rhizome Extraction
Whole V. parviflorum plants were collected by the treating medical toxicology
physicians at the same site where patients 3, 4, 5, and 6 gathered the plants they
consumed. Roots and rhizomes were separated from the plant, diced, and lyophilized for
24 hrs before being ground into a fine powder. Ethanol (100 mL of 95%, Decon
Laboratories, Inc.) was added to 10 g of dried V. parviflorum powder to form a slurry that
was sonicated for 30 min and stirred for 24 hrs at room temperature. The mixture was
filtered to produce a clear and brown supernatant that was then concentrated via rotary
evaporation. Removal of solvent resulted in a viscous dark brown extract to which 2 mL
of 100% ethanol (Decon Laboratories, Inc.) was added. This extract was filtered through
a 0.45 μm nylon syringe filter and placed in an autosampler vial for steroidal alkaloid
characterization via HPLC-QTOF.
4.2 Blood Extraction
Chloroform was used to extract the steroidal alkaloids from patient serum. A
biphasic mixture containing 1 mL patient serum and 0.4 mL chloroform was vortexed for
1 min then centrifuged for 5 min at 14000 rpm. A 0.3 mL aliquot of the chloroform layer
was removed and evaporated to dryness under a stream of nitrogen. The remaining
residue was dissolved in 0.1 mL ethanol (100%) for HPLC-QTOF analysis. A calibration
curve consisting of 5, 1, 0.5, 0.1, and 0.05 μg/mL of standard was formed using
commercially available cyclopamine (≥95%, PhytoLab GmbH & Co. KG), veratramine
(>98%, TCI America), veratridine (≥98%, Tocris Bioscience), muldamine (99%, Logan
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Natural Products), and jervine (≥95%, PhytoLab GmbH & Co. KG) to quantify steroidal
alkaloids in patient serum.
4.3 Breast Milk Extraction
A 0.5 mL aliquot of patient breast milk was diluted with 0.5 mL ammonium
hydroxide (29%) and loaded onto a supported liquid extraction (SLE) column (Agilent
Chem Elut S) and allowed to adsorb onto the solid phase for 10 min. Following
adsorption, 10 mL of chloroform was added to the column and eluted on a vacuum
manifold with -0.2 bar applied vacuum for 30 sec. The eluted solvent was filtered through
a 0.45 μm PVDF syringe filter and evaporated to dryness under a stream of nitrogen.
Remaining residue was dissolved in 0.1 mL ethanol (100%) and analyzed via HPLCQTOF. Quantification of alkaloids in breast milk was performed using a calibration curve
consisting of 5, 1, 0.5, 0.1, and 0.05 μg/mL of alkaloid standards.
4.4 Steroidal Alkaloid Identification
Veratrum steroidal alkaloids were identified in blood, breastmilk, and
root/rhizome extracts using HPLC-QTOF and commercially available standards.
Analysis was performed on a Bruker maXis ESI Q-TOF mass spectrometer (Bruker
Corporation, Billerica, MA) coupled with a Dionex Ultimate 3000 LC system (Thermo
Scientific, Waltham, MA). The samples were injected onto a Waters Xterra MS C18
column (5 μm, 2.1 x 150 mm) maintained at 40 °C at an injection volume of 5 μL. A
gradient elution consisting of 0.1% formic acid in water (solvent A) and 0.1% formic acid
in acetonitrile (solvent B) was used with a 300 μL/min flowrate. The elution method
began at 10% solvent B before increasing to 20% solvent B after 1 min. Between minute
1 and 16, solvent B was increased to 40%. After 16.1 min, solvent B was increased to
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100% and maintained until minute 20. Solvent B was decreased to 5% at 20.1 min and
held constant until minute 25. The electrospray ionization (ESI) source was operated
under the following conditions: positive ion mode, 4000 to -500 V voltage between
capillary and end plate offset, 10.0 L/min flow rate of N2 drying gas at 200 °C.
5. Results
To identify the presence of Veratrum steroidal alkaloids within patient blood
samples, commercially available human serum was spiked at 1, 10, and 50 mg/L with
five steroidal alkaloid standards: jervine, veratramine, veratridine, cyclopamine, and
muldamine. The spiked serum underwent the described extraction procedure to not only
determine the retention time and ions produced, but to also assess the limit of detection
(LOD) and limit of quantification (LOQ) for the alkaloids (Figure 2.3). The LOD for
jervine, veratramine, veratridine, cyclopamine, and muldamine was 44, 16, 63, 45, and 38
ng/mL, respectively, while the LOQ were 134, 48, 191, 136, and 115 ng/mL,
respectively.
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Figure 2.3
Base peak chromatogram for human serum extracts. Base peak
chromatogram for patient #1 overlaid with extracted ion chromatograms for
commercially available steroidal alkaloids that were spiked to 10 mg/L into and
extracted from a human serum standard. Peaks 1-5 were identified as jervine,
veratramine, veratridine, cyclopamine, and muldamine, respectively.
The retention time for cyclopamine in the standard and patient extracts where
12.0 and 11.9 minutes, respectively (Figure 2.4). An [M+H]+ parent ion for cyclopamine
(412.32 ± 0.02 m/z) was identified in the patient #1 extract (Figure 2.4C). Jervine,
veratramine, veratridine, and muldamine were not detected in the blood extract of patient
#1.
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Figure 2.4
Serum extracts for patient #1 were compared to a cyclopamine
standard. A) Extracted ion chromatogram for cyclopamine (412.32 ± 0.02 m/z)
extracted from commercially available human serum. B) Extracted ion
chromatogram for 412.32 ± 0.05 m/z. C) Mass spectrum of the peak (RT: 12.0 min)
in chromatogram A where the observed [M+H]+ ion for cyclopamine (412.32 ± 0.02
m/z) has been identified. D) Mass spectrum of the peak (RT: 11.9 min) in
chromatogram B where the observed [M+H]+ ion for cyclopamine (412.32 ± 0.02
m/z) has been identified.
Qualitative analysis of the blood extract of patient #4 recognized jervine and
cyclopamine (Figures A.1 and A.2). The retention time for jervine was 9.1 minutes
(Figures A.1A and A.1B) and the [M+H]+ parent ion (426.30 ± 0.05 m/z) was identified
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(Figure A.1C). Cyclopamine was identified in the blood of patient #4 by the presence of
the [M+H]+ parent ion (412.32 ± 0.05 m/z) (Figure A.2C). Veratramine was identified in
the blood extract of patient #7 by the observation of the [M+H]+ parent ion (410.31 ±
0.05 m/z) (Figure A.3) and retention time of 10.0 min. Veratrum alkaloids were not
detected in blood extracts of patients 2, 3, 5, 6, and 8.
Table 2.2
Extracts

Identity and Concentration of Alkaloids Identified in Patient Blood

Patient #

Alkaloids Identified

1

Cyclopamine

4

Cyclopamine
Jervine

7

Veratramine

Veratramine and cyclopamine were the only steroidal alkaloids identified in an extract of
the breast milk of patient #2 (Figures A.4-A.6). Veratramine was identified to have a
retention time of 9.4 min and a [M+H]+ parent ion of 410.31 ± 0.02 m/z. Cyclopamine
was identified with a retention time of 11.6 min and a [M+H]+ parent ion of 412.32 ±
0.02 m/z. The concentration of veratramine (LOD = 11 ng/mL; LOQ = 34 ng/mL) in the
milk was observed to decrease in the second sample, then increase in the third sample to
a lower concentration than initially observed. The concentration of cyclopamine (LOD =
11 ng/mL; LOQ = 32 ng/mL) was below the LOQ in all samples. The fourth breast milk
sample collected on April 9 at 17:00 did not contain a detectable level of veratramine or
cyclopamine (Table 2.3).
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Table 2.3
Identity and Concentration of Steroidal Alkaloids in Patient Breast
Milk Extracts
Patient #

Date/Time of Collection

Alkaloids Identified

Concentration (ng/mL)

2

April 8 2020 at 11:30

Veratramine

405

Cyclopamine

-

Veratramine

136

Cyclopamine

-

Veratramine

303

Cyclopamine

-

-

-

April 8 2020 at 16:20

April 9 2020 at 8:00

April 9 2020 at 17:00

The root and rhizome extract of V. parviflorum yielded a chromatogram with over
53 peaks representing unique constituents (Figure 2.5). Commercially available steroidal
alkaloid standards for jervine, veratramine, veratridine, cyclopamine, and muldamine
were used to identify known alkaloids within the V. parviflorum extract. All steroidal
alkaloid standards were present in the plant extract with the exception of veratridine
(Figure A.7-A.10).
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Figure 2.5
V. parviflorum root and rhizome ethanolic extract. Peaks labelled 1-4
correspond to jervine, veratramine, cyclopamine, and muldamine, respectively.
6. Discussion
Veratrum steroidal alkaloids are recognized for their toxicity and have been
implicated in multiple cases of inadvertent poisoning.15, 23-30 An ethanolic extract of the
roots and rhizomes of V. parviflorum resulted in the identification of four common
Veratrum steroidal alkaloids: cyclopamine, veratramine, jervine, and muldamine.
Contrary to the results presented by Anwar et al., where cyclopamine, veratramine,
verazine, and veratridine were identified, veratridine was not identified in the present
extract of V. parviflorum.15 A standard of verazine could not be obtained, however, an
EIC for 398.3553 m/z presented several peaks suggesting that the previously identified
alkaloid may still be observed given the appropriate reference material. Variation in the
presence of veratridine in V. parviflorum may be due to differences in growth stage,
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harvest time, or harvest location.85 The growth stage, time of harvest, harvest location,
and part of the plant for V. californicum has shown to influence the alkaloid composition
in plant material.85 Although the poisoning described by Anwar et al. also occurred in
April, it is possible that the V. parviflorum used in that study was harvested at an earlier
date, in a different location, or at a different stage of growth.
This study provides the first evidence for the presence of muldamine and jervine
within V. parviflorum. Jervine has previously been isolated from Veratrum spp. including
V. nigrum L., V. californicum, V. album, and V. viride, whereas muldamine has only been
isolated from V. californicum.44,56,85-88 Symptoms exhibited by the patients in the present
study, including nausea, vomiting, hypotension, and bradycardia, were consistent with
those commonly observed for Veratrum toxicity. Additionally, the time between
ingestion and the appearance of symptoms was consistent with prior cases.15,23-30
The identification of veratramine and cyclopamine in breast milk suggests that the
indirect exposure of an infant via ingestion is possible, although the clinical significance
is unknown. The alkaloid profiles and concentrations observed in breast milk may differ
from blood. In samples from patient 2, Veratrum alkaloids were only detected in the
breast milk, but not blood, even though the first milk sample was collected the morning
after her ED visit. Veratramine and cyclopamine were identified, although the
cyclopamine concentrations were below the LOQ. Lipophilicity may account for the
presence of these alkaloids in breast milk even after they are no longer detectable in the
blood. SwissADME was used to predict the partition coefficients for each of the
Veratrum steroidal alkaloids. As predicted by SwissADME, veratramine is the most
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lipophilic of the three alkaloids we identified (LogPo/w = 4.30), followed by cyclopamine
(LogPo/w = 4.16), with jervine being the least lipophilic (LogPo/w = 3.53).
Veratramine has been identified to exert bradycardic and teratogenic effects
through the inhibition of Na+ ion channels and Hedgehog signaling, respectively, with an
LD50 of 15.9 mg/kg when administered to Kunming mice intragrastrically.58,60
Furthermore, veratramine is a releaser and uptake inhibitor of 5-HT.58,60 Cyclopamine has
also been identified as an inhibitor of the Hedgehog signaling pathway with an LD50 of
43.5 mg/kg when administered to 129S11/Svlmj mice intraperitoneally.6,54,82 Excretion of
xenobiotics in breast milk can depend on many factors such as plasma levels and physical
properties including lipophilicity, protein binding, and ionization. Concentrations of
Veratrum alkaloids in milk may also vary with different collection times. We observed
higher veratramine concentrations in milk samples collected in the morning compared to
the afternoon. The patient reported that she had not nursed or pumped milk for 16 hours
prior to collection of the first sample included in our analysis. It is possible that more
Veratrum alkaloids accumulated overnight due to less frequent nursing and pumping,
leading to higher concentrations in milk expressed in the morning compared to other
times during the day. Although breast milk samples were collected four times over a 29.5
hour period, additional time points over a longer collection period are required to
determine the half-life of veratramine and cyclopamine more accurately. Variation in
observed concentrations of veratramine may be due to acute changes in the breast milk
composition and chemical properties of the small molecule.89,90 Additional study
regarding the pharmacokinetics of Veratrum steroidal alkaloids in relation to
concentration in breast milk may be beneficial.
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Three of the eight patients had detectable levels of Veratrum alkaloids in the
blood. Due to the small sample size, we were unable to characterize associations between
the presence of certain alkaloids or their concentrations with severity of illness. As the
blood specimens were convenience samples left over from routine clinical testing, there
were limitations including differences in collection times, storage conditions, and the
prolonged time in storage before analysis.
Cross-reactivity with digoxin clinical chemistry assays have been reported in
patients who have ingested Veratrum species.32 Only one patient in our study had a
positive digoxin assay, although she had mild symptoms. There was no discernable
association between symptom severity and digoxin assay results.
7. Conclusion
This study sought to identify toxic steroidal alkaloids in the blood of eight
patients and breast milk for one of them that inadvertently ingested V. parviflorum. Four
alkaloids were identified in an ethanolic extract from the roots of V. parviflorum: jervine,
veratramine, cyclopamine, and muldamine. An efficient and effective method was
developed for the extraction of steroidal alkaloids from patient samples, leading to the
identification of cyclopamine, jervine, and veratramine in patient blood, and veratramine
and cyclopamine in patient breast milk. The presence of steroidal alkaloids in breast milk
suggests that the indirect poisoning of a breastfeeding infant should be considered in
cases of suspected Veratrum poisonings.
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CHAPTER THREE: ASSESSMENT OF HEDGEHOG SIGNALING INHIBITION BY
STEROIDAL ALKALOIDS IN VERATRUM PARVIFLORUM
1. Introduction
Natural products derived from marine and terrestrial sources have been used for
the treatment of various illnesses and conditions for millennia.91 Mesopotamian clay
tablets dating from around 2600 BCE were inscribed with an estimated 100 plant-derived
therapeutics used to treat symptoms including inflammation, parasitic infections, and
coughing.92,93 Similarly, ancient Chinese medicines dating from around 1100 BCE
described herbal remedies for the prevention and treatment of various diseases.92,94 These
records indicate that plants have been a major source for the development of
sophisticated medical formulations.92 The broad medical applications of plant-derived
therapeutics result from an abundance of structurally unique and chemically diverse
compounds.95 These compounds are commonly secondary metabolites that have evolved
in plants through millions of years of evolution, driven by various ecological and
physiological stressors, including defense from herbivores, pathogens, and abiotic
conditions. Plant secondary metabolites facilitate interactions with pollinators, plant-plant
signaling, and attracting the predators of herbivores.96
The Veratrum genus is composed of perennial flowering herbs reported to have
been incorporated into Eastern and Western traditional herbal medicines. These herbal
treatments have been used for conditions such as rheumatism, sore throat, aphasia,
chronic malaria, and venereal diseases.7,10 For over a century, there has been great
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interest in utilizing the steroidal alkaloids produced by the Veratrum spp. in modern
medicine due to their potent physiological effects. Initial investigations performed in
1867 by Albert von Bezold and Ludwig Hirt identified that the onset of hypotension and
bradycardia occurred after the administration of veratrine, a mixture of Veratrum derived
alkaloids, to a rabbit.38 Jarisch and Richter later identified that the hypotensive and
bradycardic effects of veratrine were a result of the transmission of a reflex action in the
ventricles of the heart through the afferent and efferent pathways of the vagus nerve.6,36
Dr. Charles Osgood noted the similar physiological effects of veratrine to V. viride, a
Veratrum spp. native to North America, and recommended the use of its extract for
inflammatory diseases. Preparations of V. viride extracts were commonly prescribed for
high blood pressure from the late 19th to mid-20th century. However, by the 1970s, V.
viride alkaloids were abandoned as a prescribed therapeutic due to an unreliable supply,
clinical limitations, and the development of more effective antihypertensive drugs.6
In the 1950s, sheep herders observed that between 1-25% of lambs born from
ewes bred in the alpine meadows of South Central and Southwestern Idaho were beset
with cyclopean-type developmental defects.42 The malformations were originally thought
to be congenital, however, further investigations identified that the deformations resulted
from ewes feeding on Veratrum californicum, also known as false hellebore or corn lily,
between day 10 and 15 of gestation.42,43 Keeler and Binns later identified that the
steroidal alkaloids cyclopamine, cycloposine, jervine, and veratrosine were teratogenic
agents contributing to the cyclopean malformations.44 The mechanism in which these
alkaloids exert the teratogenic effect is through inhibition of the Hedgehog (Hh) signaling
pathway by directly binding to the transmembrane protein Smoothened (Smo).4,39 The Hh
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pathway is vital to embryo development and cell proliferation, however, uncontrolled
activation is linked to the development of over 20 cancers, most notably basal cell
carcinoma and acute myeloid leukemia.5,97
As a result of this relationship, Veratrum-derived steroidal alkaloids have been
investigated for their ability to antagonize Hh signaling. A number of these steroidal
alkaloids have been evaluated for Hh antagonism and proven effective in reducing cancer
activity.4,39-41,62,98-100 The jervanine type alkaloid cyclopamine has received the most
study and remains as one of the most potent naturally occurring Hh inhibitors.6,62 This
alkaloid has been observed to reduce Hh signaling in Shh light II cells, block the
proliferation of murine medulloblastoma in vitro, and induce cell death in human
medulloblastomas.62,99 One study observed that the treatment of cyclopamine in
combination with paclitaxel induced improved tumor apoptosis in comparison to
treatments only consisting of paclitaxel.98 These results suggested that a Hedgehog
signaling could be a prospective drug target for cancer cells that have developed a
resistance to mitotic inhibitor chemotherapies.98 Despite the observed bioactivity,
Veratrum alkaloids such as cyclopamine have limited therapeutic use due to poor
aqueous solubility and instability in acidic chemical environments.6 The pharmaceutical
industry has since development more potent synthetic and semi-synthetic drugs including
vismodegib, sonidegib, glasdegib, and patidegib (IPI-926) that antagonize Smo. With the
exception of IPI-926, which is currently undergoing Phase III clinical trials, these drugs
have been approved by the United States Food and Drug Administration (FDA) for the
treatment of basal cell carcinoma (BCC) and acute myeloid leukemia (AML).5,101
Although proven to be effective anticancer drugs, recurrence after treatment is common
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due to mutations in Smo.102-104 Additional investigation of Veratrum spp. may lead to the
identification of novel alkaloids and alkaloid mixtures with potential to serve as
chemotherapeutics or as guides for the development of semi-synthetic and synthetic
drugs.
V. parviflorum, commonly known as the Appalachian bunchflower, is a lesserknown species of the Veratrum genus native to the mountain slopes of the Southeastern
United States. In contrast to other Veratrum spp., such as V. album and V. viride¸ V.
parviflorum has not been reported to be used in traditional medicines.6 Instead, this plant
has been implicated in the accidental poisoning of foragers who mistake the plant for
wild leeks (Allium tricoccum) in its adolescent stages (Figure 3.1).15 Veratrum poisoning
may be characterized by gastrointestinal unrest and a Bezold-Jarisch reflex resulting from
neuronal sodium channel hyperpermeability.15,33 Cardiovascular toxicity is generally
observed in patients due to the propensity of the alkaloids to bind to voltage-gated
sodium ion channels, causing the channels to remain open.14,15,33,105

Figure 3.1

In situ Veratrum parviflorum(Appalacian bunchflower) (Top) and
Allium tricoccum (wild leek) (Bottom).20,106
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A qualitative investigation of V. parviflorum identified four known alkaloids from
an ethanolic extract of the roots and rhizome: verazine, veratramine, veratridine, and
cyclopamine.15 Of these alkaloids, cyclopamine and veratramine have been identified as a
Hh pathway inhibitor.41,107,108 The study of Veratrum sect. Fuscoveratrum species
including V. mackii, V. mengtzeanum, V. stenophyllum, and V. taliense has led to the
discovery of alkaloids thought to be unique to specific species.7 Due to the classification
of V. parviflorum in sect. Fuscoveratrum and the lack of information regarding its
phytochemistry, additional study of the steroidal alkaloids extracted from the root and
rhizome may yield novel alkaloids that promote inhibition of Hh pathway signaling. In
the present study, HPLC-MS was used to identify steroidal alkaloids within an extract of
the roots and rhizomes of V. parviflorum. Following identification, a series of treatments
containing alkaloids found within the plant were made using commercially available
standards and assessed using a Shh-Light II cell bioactivity assay. Combinations of these
steroidal alkaloid standards were developed at concentrations that matched those found
within the plant extract. A comparison of bioactivity measurements for alkaloid mixtures
and the V. parviflorum extract may provide insights into the presence of less abundant
alkaloids that are antagonistic to the Hh pathway.
2. Materials and Methods
2.1 Chemicals and Solvents
Acetonitrile (>99% purity), 95% ethanol, 100% ethanol, trifluoroacetic acid
(>99.9% purity), Dulbecco’s Modified Eagle Medium, Geneticin, Zeocin, PenicillinStreptomycin (10,000 U/mL), and fetal bovine serum were purchased from ThermoFisher
Scientific. Recombinant mouse Sonic Hedgehog/Shh, N-terminus protein was purchased
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from R&D Systems. The Dual-Luciferase Reporter Assay System was purchased from
Promega. Cyclopamine (≥95% purity) and jervine (≥95% purity) were purchased from
PhytoLab GmbH & Co. KG, veratramine (>98% purity) was purchased from TCI
America, veratridine (≥98% purity) was purchased from Tocris Bioscience, and
muldamine (99% purity) was purchased from Logan Natural Products.
2.2 Alkaloid Extraction
The roots and rhizome of V. parviflorum were separated and lyophilized for 24
hrs then ground into a fine powder. One hundred milliliters of 95% ethanol were added to
10 g of dried V. parviflorum powder. The resulting slurry was sonicated for 30 min and
stirred at room temperature for 24 hrs. The mixture was vacuum filtered, producing a
clear and brown filtrate, and concentrated by rotary evaporation. Removal of the
extraction solvent resulted in a viscous extract which was then dissolved in 2 mL of
100% ethanol. The extract was filtered through a 0.45 μm PTFE syringe filter into an
autosampler vial for HPLC-QTOF analysis.
2.3 Alkaloid Identification
Veratrum steroidal alkaloids were identified in the root/rhizome extracts using
HPLC-QTOF and commercially available standards. Analysis was performed on a
Bruker maXis ESI Q-TOF mass spectrometer (Bruker Corporation, Billerica, MA)
coupled with a Dionex Ultimate 3000 LC system (Thermo Scientific, Waltham, MA).
The samples were injected onto a Waters Xterra MS C18 column (5 μm, 2.1 x 150 mm)
maintained at 40 °C at an injection volume of 5 μL. A gradient elution consisting of 0.1%
formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) was
used with a 300 μL/min flowrate. The elution method began at 10% solvent B before
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increasing to 20% solvent B after 1 min. Between minute 1 and 16, solvent B was
increased to 40%. After 16.1 min, solvent B was increased to 100% and maintained until
minute 20. Solvent B was decreased to 5% at 20.1 min and held constant until minute 25.
The electrospray ionization (ESI) source was operated under the following conditions:
positive ion mode, 4000 to -500 V voltage between capillary and end plate offset, 10.0
L/min flow rate of N2 drying gas at 200 °C.
2.4 Alkaloid Quantification
Alkaloids identified within the extract were quantified using commercially
available standards. A calibration curve consisting of five points between 65 and 6.88
mg/L was formed for cyclopamine, veratramine, jervine, and muldamine. An Agilent
InfinityLab LC/MSD. The sample was injected onto a Waters Xterra MS C18 column (5
μm, 2.1 x 150 mm) maintained at 40 °C at a volume of 10 μL. The ESI source was
operated with a capillary voltage set to 4000 V. The N2 drying gas temperature was set to
300 °C with a flow rate of 7.0 L/min and nebulizer pressure of 15 psi. The same solvent
gradient was used as described in the previously.
2.5 Cell Culture and Bioactivity Assay
Shh Light II cells (JHU-068) were grown in DMEM supplemented with 0.4
mg/mL geneticin, 0.15 mg/mL ZeocinTM, 1% Penicillin-Streptomycin, and 10 % fetal
bovine serum. The cells were grown at 37 °C in an atmosphere of 5% CO2 in air, and
100% relative humidity. Shh Light II cells were seeded into a 95-well plate at a seeding
density of 10,000 cells/well and grown to confluence in the previously described growth
media. Alkaloid treatments were dissolved in 100% ethanol and added to DMEM
containing 0.5% fetal bovine serum and 1% Penicillin-Streptomycin with a final ethanol
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concentration of 1%. After the cells become confluent, the growth media was replaced
with DMEM supplemented with 0.5% fetal bovine serum and 1% PenicillinStreptomycin (starvation media), 10 ng of N-terminal mouse recombinant Shh dissolved
in DMEM, and the alkaloid treatment. The positive control was treated with 10 ng of Nterminal mouse recombinant Shh dissolved in DMEM while the negative control only
contained starvation media. Gli activity was assessed 48 hours following treatment with
the Dual-Luciferase® Reporter Assay System from Promega. Luminescence resulting
from the transcription of the luciferase reporter with eight copies of the Gli binding site
was measured using a Synergy H1 Hybrid Multi-Mode Reader. Each treatment was
performed five times.
3. Results
3.1 Alkaloid Identification and Quantification
Qualitative analysis of the V. parviflorum extract revealed four alkaloids:
cyclopamine, veratramine, muldamine, and jervine (Figure 3.2). These alkaloids were
identified by comparing the respective retention times and mass spectra to commercially
available standards. Cyclopamine, veratramine, muldamine, and jervine had retention
times of 11.5, 9.4, 15.7, and 8.8 min, respectively. The mass spectra presented in Figure
3.3 depict the [M+H]+ ions for each alkaloid in the extract. The [M+H]+ ions for
cyclopamine, veratramine, muldamine, and jervine of 412.32 ± 0.02, 410.30 ± 0.02,
458.36 ± 0.02, 426.30±0.02 m/z, respectively.
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Figure 3.2
Chromatogram of V. parviflorum extract collected the HPLC-QTOF.
Peaks labeled 1-4 were identified as jervine, veratramine, cyclopamine, and
muldamine, respectively.

Figure 3.3
Mass spectra for identified steroidal alkaloids in V. parviflorum
extract. Panels A-D provide the mass spectra for jervine, veratramine, cyclopamine,
and muldamine, respectively. Jervine, veratramine, cyclopamine, and muldamine
were identified by the observed [M+H]+ ions of 426.31 ± 0.02, 410.33 ± 0.02, 412.33 ±
0.02, and 458.37 ± 0.02, respectively.
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The concentration of the steroidal alkaloids in V. parviflorum were calculated
using calibration curves with R2 > 0.99. The concentration of cyclopamine, veratramine,
muldamine, and jervine in the root and rhizome extract were 10.2, 4.9, 0.4, and 3.6 mg/L,
respectively (Table 3.1). These concentrations were then replicated using commercially
available standards and used as a treatment condition in the Shh-Light II cell bioactivity
assay.
Table 3.1
Extract

Concentration of Identified Steroidal Alkaloids in V. parviflorum

Steroidal Alkaloid Identified

Concentration (mg/L)

Cyclopamine

10.2

Veratramine

4.9

Muldamine

0.4

Jervine

3.6

3.2 Bioactivity Assessment
Steroidal alkaloid treatments were made using commercially available standards
(Table 3.2). The extract copy high and low treatments consisted of steroidal alkaloid
concentrations that matched those found within the plant extract. The purpose of
evaluating Hh signaling using this treatment was to identify if there were additional
alkaloids within the extract with Hh inhibitory properties. The bioactivity evaluation of
the V. parviflorum steroidal alkaloids identified that there was no statistically significant
difference between the low and high treatments for cyclopamine and muldamine (Figure
3.4). At low concentrations, cyclopamine was the most potent inhibitor while veratramine
was the most effective inhibitor at high concentrations. A comparison of the low copy
extract to the low extract treatment indicated that there was a statistically significant
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difference (p<0.01). This suggests that there are additional components within the V.
parviflorum extract that contribute to enhanced Hh inhibition.
Table 3.2

Alkaloid Treatments for Shh-Light II Cell Assay

Treatment
Condition

Cyclopamine
(µM)

Veratramine
(µM)

Veratridine Muldamine Jervine
(µM)
(µM)
(µM)

Cyclopamine High

1

-

-

-

-

Cyclopamine Low

0.1

-

-

-

-

Veratramine High

-

1

-

-

-

Veratramine Low

-

0.1

-

-

-

Veratridine High

-

-

1

-

-

Veratridine Low

-

-

0.1

-

-

Muldamine High

-

-

-

1

-

Muldamine Low

-

-

-

0.1

-

Jervine High

-

-

-

-

1

Jervine Low

-

-

-

-

0.1

Extract Copy High

0.2

0.1

-

0.01

0.08

Extract Copy Low

0.02

0.01

-

0.001

0.008

Relative Gli-Reporter Activity (RLU)

51
60
50
40
30
20
10
0

Figure 3.4
Bioactivity results for the Shh-Light II cell assay. There was a
statistically significant difference between the high and low treatment conditions for
veratramine (p<0.01), veratridine (p<0.05), jervine (p<0.05), and the extract copies
(p<0.05). The extract low treatment exhibited lower relative Gli-reporter activity
than the low extract copy treatment (p<0.01).
4. Discussion
The two primary objectives of the current study were to 1) identify steroidal
alkaloids with an extract of V. parviflorum and evaluate their ability to inhibit the Hh
signaling pathway, and 2) determine if there were additional alkaloids within the V.
parviflorum extract by comparing the Hh inhibition of the extract to standard mixtures of
alkaloids consisting of identical concentrations of cyclopamine, veratramine, muldamine,
and jervine.
The qualitative investigation regarding the steroidal alkaloid content of V.
parviflorum resulted in the identification of cyclopamine, veratramine, jervine, and
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muldamine. Cyclopamine and veratramine have been previously identified within the
plant, however, jervine and muldamine are novel to this species.15 Jervine has been
previously isolated in V. nigrum L., V. californicum, V. album, and V. viride, while
muldamine has only been isolated from V. californicum.44,56,85-88 In addition to
cyclopamine and veratramine, Anwar et al. identified verazine and veratridine within the
root and rhizome extract.15 An extracted ion chromatogram for the expected [M+H]+ ion
for verazine (398.3423 m/z) presents several peaks suggesting that the compound may be
present but remains unidentified due to the unavailability of a commercially available
standard. The absence of veratridine in the V. parviflorum extract may be due to
differences in time of harvest, growth stage, geographic location.85. One study on V.
californicum observed variation in steroidal alkaloid content given these factors.85
The inhibition of Hh signaling in Shh-Light II cells was evaluated using luciferase
reporter assay. Results from this assessment suggested that there was a statistically
significant difference between the high and low treatments for veratramine (p<0.01),
veratridine (p<0.05), jervine (p<0.05), and the extract copies (p<0.05). There was a
general trend of lower relative Gli-reporter activity in the high concentration treatments
compared to the low concentration treatments. Previous work identified that
cyclopamine, veratramine, jervine, and muldamine inhibit Hh signaling.41,63,87,107,108 The
copy extract high treatment provided a lower Gli-reporter activity than observed for the
alkaloid treatments consisting of a single analyte. Although lower Gli-reporter activity
was observed, enhancement of Hh inhibition seems to be additive rather than synergistic.
Combinations of steroidal alkaloids from V. californicum have been observed to improve
Hh signaling inhibition in Shh-Light II cells in an additive trend.41 A comparison of the
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high and low copy extract treatments to the high and low extract treatments indicated that
there may be additional compounds within the extract of V. parviflorum with Hh
antagonistic properties. Further studies of the V. parviflorum extract may include the
isolation, characterization, and bioactivity evaluation of less abundant steroidal alkaloids.
5. Conclusion
V. parviflorum is an underexplored plant species that has been identified to
contain steroidal alkaloids that inhibit the Hh signaling pathway. The present study
sought to identify alkaloids within an ethanolic extract of V. parviflorum’s roots and
rhizome and assess the bioactivity of these alkaloids for Hh inhibition. Cyclopamine,
veratramine, jervine, and muldamine were identified in the extract of V. parviflorum and
evaluated for Hh inhibition using Shh-Light II cells in a Dual-Luciferase® Reporter
Assay System. There was no statistically significant difference in Hh inhibition between
the different alkaloid treatments consisting of a single analyte, however, combinations of
these alkaloids at concentrations that match those found within the plant extract provided
enhanced inhibition. Furthermore, the plant extract showed much lower levels of Glireporter activity than the copy extract treatments indicating that there may be less
abundant alkaloids within the extract that inhibit Hh signaling.
CHAPTER FOUR: CONCLUSION AND FUTURE DIRECTIONS
The foundation for modern therapeutic development has been established by
secondary metabolites originating from marine and terrestrial sources. Out of an
estimated 70,000 plant species used throughout history for medicinal purposes, more than
3,000 plants are reported to contain compounds with anticancer properties.1,2 The
Veratrum genus of plants has played a critical role in the development of a class of cancer
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therapeutics, called Hedgehog pathway inhibitors, that target cancers including basal cell
carcinoma and acute myeloid leukemia.5 Although proven effective at treating cancers,
recurrence after treatment is common due to mutations in Smo.102-104 Investigating
underexplored Veratrum spp. may yield novel steroidal alkaloids with anticancer
properties
This project investigated the underexplored plant species V. parviflorum
following the accidental poisoning of eight individuals. Prior to this work, only four
steroidal alkaloids had been identified in an extract of this plant’s roots and rhizome:
cyclopamine, veratramine, veratridine, and verazine. An analysis of patient blood and
breast milk revealed the presence of cyclopamine and jervine in the blood, and
cyclopamine and veratramine in the breast milk. Investigation into the alkaloid content
within the roots and rhizome of V. parviflorum resulted in the identification of two
alkaloids novel to this Veratrum spp., muldamine and jervine. The bioactivity assessment
of the steroidal alkaloids identified in V. parviflorum suggests there may be additional
steroidal alkaloids that contribute to Hh inhibition in Shh-Light II cells.
Future work could be directed towards the isolation, characterization, and
bioactivity evaluation of steroidal alkaloids in V. parviflorum that do not have
commercially available standards. Although the current study revealed two alkaloids new
to this species, these alkaloids have already been studied for their ability to antagonize
the Hh pathway. 41,87,107,108 A comparison of the bioactivity results for the plant extract
and the extract copy that contains cyclopamine, veratramine, jervine, and muldamine at
the same concentrations as found in the plant extract suggested that there are additional
alkaloids that inhibit Hh signaling to a greater extent.
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In addition to identifying novel steroidal alkaloids, there remains great area to
investigate regarding the biosynthesis of Veratrum steroidal alkaloids. Augustin et al.
identified four enzymes that convert cholesterol to verazine, however, the proceeding
biosynthetic steps leading to compounds such as cyclopamine, veratramine, veratridine,
jervine, and muldamine remain unknown.68 Elucidating these biosynthetic pathways
would not only provide insights into how such structurally diverse compounds with wide
ranges of bioactivities form, but also into how appreciable amounts of Veratrum steroidal
alkaloids may be generated. Currently, most commercially available Veratrum steroidal
alkaloids are extracted and isolated from plant material. There have been efforts directed
towards the synthesis of these compounds, however, such endeavors require complex
reactions and provide low yields. For example, the biomimetic and diastereoselective
synthesis of cyclopamine from dehydroepiandrosterone involves twenty steps with a 1%
overall yield.109 If the enzymes involved in the biosynthesis of Veratrum steroidal
alkaloids are identified, chemoenzymatic syntheses could offer one method for producing
larger quantities of these compounds for use in experiments pertinent to drug discovery
such as bioactivity assays or pharmacokinetic studies.
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APPENDIX A
Chapter Two Supplemental Figures
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Figure A.1 Serum extracts for patient #2 were compared to a jervine standard.
A) Extracted ion chromatogram for jervine extracted from commercially available
human serum. B) Extracted ion chromatogram for 426.30 ± 0.05 m/z. C) Mass
spectrum of the peak (RT: 9.1 min) in chromatogram A where the observed
[M+H]+ ion for jervine (426.30 ± 0.05 m/z) has been identified. D) Mass spectrum of
the peak (RT: 9.1 min) in chromatogram B where the observed [M+H]+ ion for
jervine (426.30 ± 0.05 m/z) has been identified.
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Figure A.2 Serum extracts for patient #2 were compared to a cyclopamine
standard. A) Extracted ion chromatogram for cyclopamine extracted from
commercially available human serum. B) Extracted ion chromatogram for 412.32 ±
0.02 m/z. C) Mass spectrum of the peak (RT: 12.0 min) in chromatogram A where
the observed [M+H]+ ion for cyclopamine (412.32 ± 0.02 m/z) has been identified.
D) Mass spectrum of the peak (RT: 12.1 min) in chromatogram B where the
observed [M+H]+ ion for cyclopamine (412.32 ± 0.02 m/z) has been identified.
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Figure A.3 Serum extracts for patient #7 were compared to a veratramine
standard. A) Extracted ion chromatogram for veratramine extracted from
commercially available human serum. B) Extracted ion chromatogram for 410.30 ±
0.02 m/z. C) Mass spectrum of the peak (RT: 9.8 min) in chromatogram A where the
observed [M+H]+ ion for veratramine (410.30 ± 0.02 m/z) has been identified. D)
Mass spectrum of the peak (RT: 10.0 min) in chromatogram B where the observed
[M+H]+ ion for veratramine (410.30 ± 0.02 m/z) has been identified.
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Figure A.4

Base peak chromatogram of the extract from the breast milk sample
collected on April 8, 2020 at 11:30.
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Figure A.5 Breast milk extracts for patient #2 were compared to a veratramine
standard that was extracted from breast milk spiked at 1 mg/L. A) Extracted ion
chromatogram for veratramine standard extracted from spiked breast milk. B)
Extracted ion chromatogram for 410.30 ± 0.02 m/z. C) Mass spectrum of the peak
(RT: 9.4 min) in chromatogram A where the observed [M+H]+ ion for veratramine
(410.31 ± 0.02 m/z) has been identified. D) Mass spectrum of the peak (RT: 9.4 min)
in chromatogram B where the observed [M+H]+ ion for veratramine (410.31 ± 0.02
m/z) has been identified.
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Figure A.6 Breast milk extracts for patient #2 were compared to a cyclopamine
standard that was extracted from breast milk spiked at 1 ppm. A) Extracted ion
chromatogram for cyclopamine standard extracted from spiked breast milk. B)
Extracted ion chromatogram for 412.32 ± 0.02 m/z. C) Mass spectrum of the peak
(RT: 11.5 min) in chromatogram A where the observed [M+H]+ ion for cyclopamine
(412.32 ± 0.02 m/z) has been identified. D) Mass spectrum of the peak (RT: 11.6
min) in chromatogram B where the observed [M+H]+ ion for cyclopamine (412.32 ±
0.02 m/z) has been identified.
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Figure A.7 V. parviflorum ethanolic extract alkaloid at Rt of 15.7-15.8 min
corresponding to muldamine. A) Extracted ion chromatogram for standard
muldamine (RT: 15.7). B) Plant extract extracted ion chromatogram for 458.36 ±
0.02 m/z. C) Mass spectrum of the peak (RT: 15.7 min) in chromatogram A where
the observed [M+H]+ ion for muldamine (458.36 ± 0.02 m/z) has been identified. D)
Mass spectrum of the peak (RT: 15.8 min) in chromatogram B where the observed
[M+H]+ ion for muldamine (458.37 ± 0.02 m/z) has been identified.
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Figure A.8 V. parviflorum ethanolic extract alkaloid at Rt of 8.8 min
corresponding to jervine. A) Extracted ion chromatogram for standard jervine (RT:
8.8). B) Plant extract extracted ion chromatogram for 426.30 ± 0.02 m/z. C) Mass
spectrum of the peak (RT: 8.8 min) in chromatogram A where the observed [M+H]+
ion for jervine (426.30 ± 0.02 m/z) has been identified. D) Mass spectrum of the peak
(RT: 8.8 min) in chromatogram B where the observed [M+H]+ ion for jervine
(426.30 ± 0.02 m/z) has been identified.
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Figure A.9 V. parviflorum ethanolic extract alkaloid at Rt of 9.4-9.5 min
corresponding to veratramine. A) Extracted ion chromatogram for standard
veratramine (RT: 9.4). B) Plant extract extracted ion chromatogram for 410.30 ±
0.02 m/z. C) Mass spectrum of the peak (RT: 9.4 min) in chromatogram A where the
observed [M+H]+ ion for veratramine (410.30 ± 0.02 m/z) has been identified. D)
Mass spectrum of the peak (RT: 9.5 min) in chromatogram B where the observed
[M+H]+ ion for veratramine (410.30 ± 0.02 m/z) has been identified.
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Figure A.10 V. parviflorum ethanolic extract alkaloid at Rt of 11.5-11.8 min
corresponding to cyclopamine. A) Extracted ion chromatogram for standard
cyclopamine (RT: 11.5). B) Plant extract extracted ion chromatogram for 412.32 ±
0.02 m/z. C) Mass spectrum of the peak (RT: 11.5 min) in chromatogram A where
the observed [M+H]+ ion for cyclopamine (412.32 ± 0.02 m/z) has been identified. D)
Mass spectrum of the peak (RT: 11.8 min) in chromatogram B where the observed
[M+H]+ ion for cyclopamine (412.32 ± 0.02 m/z) has been identified.

